Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Exclusion Criteria

• •1. Used a prohibited concomitant product or procedure to treat psoriasis during parent study
• •2. Had a serious adverse event (SAE) that was potentially related to treatment or experienced an adverse event (AE) that led to permanent discontinuation of treatment in the parent study
• •3. History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's completion of the study
• •4. Known hypersensitivity to tapinarof